The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
GlobalData on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While people with multiple myeloma can live for ...
The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...
The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma. The U.S.
The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
Bristol Myers Squibb BMY announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). The phase III EXCALIBER-RRMM (NCT04975997) is ...
Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback